PUBLISHER: Grand View Research | PRODUCT CODE: 1493355
PUBLISHER: Grand View Research | PRODUCT CODE: 1493355
The U.S. flow cytometry market size is anticipated to reach USD 2.61 billion by 2030 and is growing at a CAGR of 6.8% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market for flow cytometry is expanding faster in the U.S. owing to increased cancer cases and other chronic illnesses. According to the American Cancer Society (ACS), there were roughly 9,270 cancer deaths among adolescents and young adults in the U.S. in 2019 who were between the ages of 15 and 39, and there were about 89,500 new cases of cancer diagnosed in 2020. These factors would drive market growth.
The COVID-19 pandemic had a positive effect on the market. For instance, in August 2020, research published in Springer discovered that flow cytometry analysis of peripheral blood mononuclear cell (PBMC) phenotype helped to predict the risk of COVID-19 clinical progression and indicated that improved antigen presentation and more effective adaptive immune responses are associated with recovery from COVID-19. The increasing frequency of infectious and chronic disorders, most notably the COVID-19 outbreak, has increased the need for technology for study and diagnosis, supporting the market's growth.
Furthermore, the U.S. has a robust healthcare infrastructure, significant healthcare spending, and widespread usage of highly advanced flow cytometry technologies. In addition, owing to research universities engaging in a wide range of research activities and having developed pharmaceutical enterprises, there is an enormous need for flow cytometry workflow for research purposes. This results from the U.S.'s substantial investment in healthcare, highly developed healthcare infrastructure, and widespread usage of cutting-edge flow cytometry technology.